Abstract |
A prospective multicenter randomized trial enrolled 104 females aged 18-55 years with acute un-complicated cystitis. The patients were randomized into two groups: 49 patients of group 1 received cefixim in a single dose 400 mg/day for 5 days; 55 patients of group 2 were given ciprofloxacin in a dose 250-500 mg twice a day for 5 days. Clinical and microbiological assessment of efficacy and safety was made before treatment and on treatment day 8 and 28. Significant differences were found between groups 1 and 2 in parameters of bacteriological and clinical efficacy. Eradication of the agent and persistent bacteriological response was seen in 95.9 and 100% patients of group 1, 66 and 100% patients of group 2, respectively. Complete and partial response was observed in 55.1 and 75.5% patients of group 1, 37.3 and 58.1% patients of group 2, respectively. Thus, cefixim in a single dose 400 mg/day for 5 days has a higher microbiological efficacy than ciprofloxacin in a dose 250-500 mg twice a day. Side effects occurred less frequently in the treatment with cefixim.
|
Authors | V V Galkin, I V Malev, E V Dovgan', S N Kozlov, V V Rafal'skiĭ |
Journal | Urologiia (Moscow, Russia : 1999)
(Urologiia)
2011 Jan-Feb
Issue 1
Pg. 13-6
ISSN: 1728-2985 [Print] Russia (Federation) |
PMID | 21504072
(Publication Type: English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Ciprofloxacin
- Cefixime
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Anti-Bacterial Agents
(administration & dosage, adverse effects, therapeutic use)
- Cefixime
(administration & dosage, adverse effects, therapeutic use)
- Ciprofloxacin
(administration & dosage, adverse effects, therapeutic use)
- Cystitis
(drug therapy, microbiology)
- Female
- Humans
- Middle Aged
- Prospective Studies
- Treatment Outcome
- Young Adult
|